📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. (2017)

First Author: Lin C

Attributed to: Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.21357

Publication URI: https://www.repository.cam.ac.uk/handle/1810/274249

Type: Journal Article/Review